GSK269962A

850664-21-0

C29H30N8O5

DMSO : >= 30 mg/mL (52.58 mM)

TGF-beta/Smad; Stem Cell/Wnt; Cell Cycle/DNA Damage

GSK269962A is a potent ROCK inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. IC50 & Target: IC50: 1.6 nM (ROCK1), 4 nM (ROCK2)^[1] In Vitro: GSK269962A IC₅₀ values of 1.6 nM toward recombinant human ROCK1. GSK269962A also exhibits more than 30-fold selectivity against a panel of serine/threonine kinases. GSK269962A induces vasorelaxation in preconstricted rat aorta with an IC₅₀ of 35 nM. Both are highly potent toward human ROCK1 with IC₅₀ of 1.6 nM for GSK269962A. On the other hand, GSK269962A has a significantly improved kinase selectivity profile with at least >30-fold selectivity against the panel of protein kinase tested^[1]. In Vivo: Oral administration of GSK269965A (0.3, 1, and 3 mg/kg) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial. The maximal effect on blood pressure is observed approximately 2 h after oral gavages for both compounds. Under a similar setting, oral administration of Y-27632 (10 and 30 mg/kg) also induced a dose-dependent decrease of blood pressure. For all three Rho kinase inhibitors, the reduction of blood pressure is accompanied by an acute, dose-dependent increase in heart rate, presumably due to the activation of baroreflex mechanism^[1].